Literature DB >> 12975333

In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes.

Amit S Kalgutkar1, Hang T Nguyen, Alfin D N Vaz, Anke Doan, Deepak K Dalvie, Dale G McLeod, John C Murray.   

Abstract

The 3-unsubstituted isoxazole ring in the anti-inflammatory drug leflunomide undergoes a unique N-O bond cleavage to the active alpha-cyanoenol metabolite A771726, which resides in the same oxidation state as the parent. In vitro studies were conducted to characterize drug-metabolizing enzyme(s) responsible for ring opening and to gain insight into the mechanism of ring opening. Under physiological conditions, leflunomide was converted to A771726 in rat and human plasma (rat plasma,t1/2 = 36 min; human plasma, t1/2 = 12 min) and whole blood (rat blood, t1/2 = 59 min; human blood, t1/2 = 43 min). Human serum albumin also catalyzed A771726 formation, albeit at a much slower rate (t1/2 = 110 min). Rat and human liver microsomes also demonstrated NADPH-dependent A771726 formation (human liver microsomes, Vmax = 1797 pmol/min/mg and Km = 274 microM). Leflunomide metabolism in microsomes was sensitive to furafylline treatment, suggesting p4501A2 involvement. 3-Methylleflunomide, which contained a 3-methyl substituent on the isoxazole ring, was resistant to ring opening in base, plasma, blood, and liver microsomes. In microsomes, two monohydroxylated metabolites were formed, and metabolite identification studies established the 3- and the 5-methyl groups on the isoxazole ring as sites of hydroxylation. These results indicate that the C3-H in leflunomide is essential for ring opening. Although A771726 formation in human liver microsomes or recombinant p4501A2 required NADPH, its formation was greatly reduced by oxygen or carbon monoxide, suggesting that the isoxazole ring opening was catalyzed by the p450Fe(II) form of the enzyme. A mechanism for the p450-mediated ring scission is proposed in which the isoxazole ring nitrogen or oxygen coordinates to the reduced form of the heme followed by charge transfer from p450Fe(II) to the C=N bond or deprotonation of the C3-H, which results in a cleavage of the N-O bond.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12975333     DOI: 10.1124/dmd.31.10.1240

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  34 in total

1.  Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level.

Authors:  Kyoung-Ah Kim; Hyun-Jin Joo; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2010-10-23       Impact factor: 2.953

2.  Using a simple HPLC approach to identify the enzymatic products of UTL-5g, a small molecule TNF-α inhibitor, from porcine esterase and from rabbit esterase.

Authors:  Kenneth Swartz; Yiguan Zhang; Frederick Valeriote; Ben Chen; Jiajiu Shaw
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-09-23       Impact factor: 3.205

3.  Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2).

Authors:  Zhonghua Pei; Rohan Mendonca; Lewis Gazzard; Richard Pastor; Leanne Goon; Amy Gustafson; Erica VanderPorten; Georgia Hatzivassiliou; Kevin Dement; Robert Cass; Po-Wai Yuen; Yamin Zhang; Guosheng Wu; Xingyu Lin; Yichin Liu; Benjamin D Sellers
Journal:  ACS Med Chem Lett       Date:  2018-04-02       Impact factor: 4.345

4.  Mitochondrial dysfunction induced by leflunomide and its active metabolite.

Authors:  Jiekun Xuan; Zhen Ren; Tao Qing; Letha Couch; Leming Shi; William H Tolleson; Lei Guo
Journal:  Toxicology       Date:  2018-02-08       Impact factor: 4.221

5.  An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.

Authors:  Rodrigo A Fuentealba; Jayne Marasa; Marc I Diamond; David Piwnica-Worms; Conrad C Weihl
Journal:  Hum Mol Genet       Date:  2011-11-03       Impact factor: 6.150

6.  Metabolism studies of a small-molecule tumor necrosis factor-alpha (TNF-α) inhibitor, UTL-5b (GBL-5b).

Authors:  Jiajiu Shaw; Brian Shay; Jack Jiang; Frederick Valeriote; Ben Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-11-05       Impact factor: 2.441

7.  Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis.

Authors:  Jun Shi; Steven J Kovacs; Yaning Wang; Thomas M Ludden; Vijay O Bhargava
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

Review 8.  Pharmacogenetics: implications for therapy in rheumatic diseases.

Authors:  Lesley Davila; Prabha Ranganathan
Journal:  Nat Rev Rheumatol       Date:  2011-08-09       Impact factor: 20.543

Review 9.  Drug interactions in the treatment of rheumatoid arthritis and psoriatic arthritis.

Authors:  Stephan Pflugbeil; Karin Böckl; Reinhold Pongratz; Marianne Leitner; Winfried Graninger; Astrid Ortner
Journal:  Rheumatol Int       Date:  2020-02-12       Impact factor: 2.631

10.  Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.

Authors:  Ashley M Hopkins; Michael D Wiese; Susanna M Proudman; Catherine E O'Doherty; Richard N Upton; David J R Foster
Journal:  Br J Clin Pharmacol       Date:  2015-10-28       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.